Dapsone and Poor venous access - a phase IV clinical study of FDA data

Summary:

Poor venous access is reported as a side effect among people who take Dapsone (dapsone), especially for people who are female, 40-49 old, also take Calcium, and have Crohn's disease.

The phase IV clinical study analyzes which people have Poor venous access when taking Dapsone. It is created by eHealthMe based on reports of 11,499 people who have side effects when taking Dapsone from the FDA, and is updated regularly.

What is Dapsone?

Dapsone has active ingredients of dapsone. It is often used in dermatitis herpetiformis. eHealthMe is studying from 11,732 Dapsone users. Check the latest studies of Dapsone.

What is Poor venous access?

Poor venous access is found to be associated with 673 drugs and 479 conditions by eHealthMe. Check the latest studies of Poor venous access.

On Jul, 10, 2026

11,499 people reported to have side effects when taking Dapsone.
Among them, 25 people (0.22%) have Poor venous access.

Among these 25 people:

What is the gender of people who have Poor venous access when taking Dapsone? *

female: 79.17 %
male: 20.83 %

What is the age of people who have Poor venous access when taking Dapsone? *

What are other drugs people take besides Dapsone? *

Calcium: 18 people, 72.00%
Benadryl: 17 people, 68.00%
Protopic: 11 people, 44.00%
Apidra Solostar: 11 people, 44.00%
Lantus: 11 people, 44.00%
Potassium: 11 people, 44.00%
Prednisone: 11 people, 44.00%
Mycophenolate Mofetil: 10 people, 40.00%
Insulin: 10 people, 40.00%
Pantoprazole: 8 people, 32.00%

What are other side effects people have besides Poor venous access? *

Headache (pain in head): 12 people, 48.00%
Abdominal Pain Upper: 12 people, 48.00%
Infusion Site Oedema (swelling from excessive accumulation of watery fluid from infusion site): 11 people, 44.00%
Canker Sores (painful, open sore in the mouth): 11 people, 44.00%
Colostomy Infection (infection of colon opening out of body): 11 people, 44.00%
Infusion Site Extravasation (flow of (blood or lymph) from infusion site): 11 people, 44.00%
Abdominal Abscess (collection of pus in abdomen): 11 people, 44.00%
Weight Fluctuation: 10 people, 40.00%
Pyoderma Gangrenosum (ulcerating condition of skin that results in heaped borders with a typical appearance): 9 people, 36.00%
Hypotension (abnormally low blood pressure): 8 people, 32.00%

What are the existing conditions these people have? *

Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 11 people, 44.00%
Myositis (inflammation of the muscles): 7 people, 28.00%
Myopathy (a muscular disease in which the muscle fibres do not function): 7 people, 28.00%
Interstitial Lung Disease: 7 people, 28.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 7 people, 28.00%
Dermatomyositis (inflammation of the skin and underlying muscle tissue, typically occurring as an autoimmune condition or associated with internal cancer): 7 people, 28.00%
Myasthenia Gravis (a chronic condition that causes muscles to tire and weaken easily): 3 people, 12.00%
Neoplasm Malignant (cancer tumour): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Dapsone and have Poor venous access?

- Check whether Poor venous access is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dapsone:

Dapsone (11,732 reports)

Browse all side effects of Dapsone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Poor venous access:

Poor venous access (673 drugs)

Browse all the conditions that are associated with Poor venous access:

Poor venous access (479 conditions)

Related publications that referenced our studies

Semira ZA, Zulfkar Q, Sameem F, "Livedo reticularis associated with dapsone therapy in a patient with chronic urticaria", Indian journal of pharmacology, 2014 Jan .
Semira ZA, Zulfkar Q, Sameem F, "Livedo reticularis associated with dapsone therapy in a patient with chronic urticaria", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on dapsone (the active ingredients of Dapsone) and Dapsone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.